Publications scientifiques en 2015

Depuis le 31/03/2025
  1. Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study.
    Bénard-Laribière A, Miremont-Salamé G, Pérault-Pochat MC, Noize P, Haramburu F; EMIR Study Group on behalf of the French network of pharmacovigilance centres.
    Fundam Clin Pharmacol. 2015
  2. Inhaler devices for chronic obstructive pulmonary disease: insights from patients and healthcare practitioners.
    Molimard M, Colthorpe P.
    J Aerosol Med Pulm Drug Deliv. 2015
  3. Parkinson's disease incidence and prevalence assessment in France using the national healthcare insurance database.
    Blin P, Dureau-Pournin C, Foubert-Samier A, Grolleau A, Corbillon E, Jové J, Lassalle R, Robinson P, Poutignat N, Droz-Perroteau C, Moore N.
    Eur J Neurol. 2015
  4. Effect of traditional Uyghur medicine abnormal Savda Munziq extract on rabbit platelet aggregation in vitro and rat arteriovenous shunt thrombosis in vivo.
    Umar A, Yimin W, Tohti I, Upur H, Berké B, Moore N.
    J Ethnopharmacol. 2015
  5. Why are benzodiazepines not yet controlled substances?
    Moore N, Pariente A, B?gaud B.
    JAMA Psychiatry. 2015
  6. Burnout: evaluation of the efficacy and tolerability of TARGET 1® for professional fatigue syndrome (burnout).
    Jacquet A, Grolleau A, Jove J, Lassalle R, Moore N.
    J Int Med Res. 2015
  7. Drugs and Sleep Apneas? A review of the French Pharmacovigilance database.
    Linselle M, Montastruc F, Jantzen H, Valnet-Rabier MB, Haramburu F, Coquerel A, Gouraud A, Perault-Pochat MC, Bagheri H, Montastruc JL.
    Therapie. 2015
  8. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
    Raschi E, Poluzzi E, Koci A, Salvo F, Pariente A, Biselli M, Moretti U, Moore N, De Ponti F.
    Br J Clin Pharmacol. 2015
  9. Is there really a link between benzodiazepine use and the risk of dementia?
    Billioti de Gage S, Pariente A, B?gaud B.
    Expert Opin Drug Saf. 2015
  10. Preventability of adverse effects of analgesics: analysis of spontaneous reports.
    Cazacu I, Miremont-Salam? G, Mogosan C, Fourrier-R?glat A, Loghin F, Haramburu F.
    Eur J Clin Pharmacol. 2015
  11. Antihypertensive drugs, hypotension, and ischemic colitis.
    Blin P.
    Am J Cardiovasc Drugs. 2015
  12. Statins in pregnancy: new safety data are reassuring, but suspension of treatment is still advisable.
    Haramburu F, Daveluy A, Miremont-Salam? G.
    BMJ. 2015
  13. Perspectives in Biological Monitoring of Inhaled Nanosized Particles.
    Rinaldo M, Andujar P, Lacourt A, Martinon L, Canal Raffin M, Dumortier P, Pairon JC, Brochard P.
    Ann Occup Hyg. 2015
  14. Signal identification in addictovigilance: the functioning of the French system.
    Jouanjus E, Gibaja V, Kahn JP, Haramburu F, Daveluy A.
    Therapie. 2015
  15. Traditional Uighur Medicine Karapxa decoction, inhibits liver xanthine oxidase and reduces serum uric acid concentrations in hyperuricemic mice and scavenges free radicals in vitro.
    Amat N, Umar A, Hoxur P, Anaydulla M, Imam G, Aziz R, Upur H, Kijjoa A, Moore N.
    BMC Complement Altern Med. 2015
  16. Effects of Cydonia oblonga Miller leaf and fruit flavonoids on blood lipids and anti-oxydant potential in hyperlipidemia rats.
    Umar A, Iskandar G, Aikemu A, Yiming W, Zhou W, Berk? B, Bégaud B, Moore N.
    J Ethnopharmacol. 2015
  17. Drug use in French children: a population-based study.
    Bénard-Laribière A, Jové J, Lassalle R, Robinson P, Droz-Perroteau C, Noize P.
    Arch Dis Child. 2015
  18. Liver transplant associated with paracetamol overdose: results from the seven-country SALT study.
    Gulmez SE, Larrey D, Pageaux GP, Bernuau J, Bissoli F, Horsmans Y, Thorburn D, McCormick PA, Stricker B, Toussi M, Lignot-Maleyran S, Micon S, Hamoud F, Lassalle R, Jov? J, Blin P, Moore N.
    Br J Clin Pharmacol. 2015
  19. Effect of Centaurium erythraea Rafn, Artemisia herba-alba Asso and Trigonella foenum-graecum L. on liver fat accumulation in C57BL/6J mice with high-fat diet-induced type 2 diabetes.
    Hamza N, Berke B, Cheze C, Marais S, Lorrain S, Abdouelfath A, Lassalle R, Carles D, Gin H, Moore N.
    J Ethnopharmacol. 2015
  20. Risk of neurodevelopmental abnormalities in children treated with propranolol.
    Labrèze C, Voisard JJ, Delarue A, Moore N.
    Br J Dermatol. 2015
  21. Utilization of psychotropic drugs by patients consulting for sleeping disorders in homeopathic and conventional primary care settings: the EPI3 cohort study.
    Grimaldi-Bensouda L, Abenhaim L, Massol J, Guillemot D, Avouac B, Duru G, Lert F, Magnier AM, Rossignol M, Rouillon F, Bégaud B; EPI3-LA-SER Group.
    Homeopathy. 2015
  22. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation.
    Bousquet J, Schunemann HJ, Fonseca J, Samolinski B, Bachert C, Canonica GW, Casale T, Cruz AA, Demoly P, Hellings P, Valiulis A, Wickman M, Zuberbier T, Bosnic-Anticevitch S, Bedbrook A, Bergmann KC, Caimmi D, Dahl R, Fokkens WJ, Grisle I, Lodrup Carlsen K, Mullol J, et al.
    Allergy. 2015
  23. Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs.
    Moore N, Pollack C, Butkerait P.
    Ther Clin Risk Manag. 2015
  24. Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?
    Freyburger G, Macouillard G, Khennoufa K, Labrouche S, Molimard M, Sztark F.
    Blood Coagul Fibrinolysis. 2015
  25. Choice of ICD-10 codes for the identification of acute coronary syndrome in the French hospitalization database.
    Bezin J, Girodet PO, Rambelomanana S, Touya M, Ferreira P, Gilleron V, Robinson P, Moore N, Pariente A.
    Fundam Clin Pharmacol. 2015
  26. Withdrawal syndrome after co-medication of opioid maintenance therapy with nalmefene: unrecognized interaction.
    Diot C, Eiden C, Roussin A, Batisse A, Boucher A, Chavant F, Daveluy A, Donadieu-Rigole H, Peyri?re H; r?seau des centres fran?ais d??addictovigilance.
    Eur J Clin Pharmacol. 2015
  27. Validation and Reproducibility of the Updated French Causality Assessment Method: an Evaluation by Pharmacovigilance Centres & Pharmaceutical Companies.
    Théophile H, Dutertre JP, Gérardin M, Valnet-Rabier MB, Bidault I, Guy C, Haramburu F, Hillaire-Buys D, Méglio C, Arimone Y.
    Therapie. 2015
  28. Benefit-Risk of Vka for Atrial Fibrillation Before Doac: a Cohort Study in a Claims and Hospitalization Database.
    Blin P, Dureau-Pournin C, Lassalle R, Abouelfath A, Droz-Perroteau C, Moore N.
    Value Health. 2015
  29. Incidence of Cardiovascular Events Following Myocardial Infarction in France: an Observational Analysis Using a Claims Database.
    Philippe F, Blin P, Laurendeau C, Bouee S, Gourmelen J, Levy Bachelot L, Leproust S, Steg PG.
    Value Health. 2015
  30. Increased Costs Due To Myocardial Infarction (Mi) In France: An Observational Analysis Using A Claims Database.
    Blin P, Philippe F, Laurendeau C, Bouee S, Gourmelen J, Levy Bachelot L, Leproust S, Steg PG.
    Value Health. 2015
  31. Assessment of Burden and Economic Impact of the Vandetanib Restricted Distribution Program in Canada.
    Frise S, Bergamasco A, Kozmenko M, Salvo F, Moride Y.
    Value Health. 2015
  32. Methodological Considerations for the Implementation of A European Mandated Retrospective Drug Utilisation Study (Dus) to Investigate the Use of Dexmedetomidine (Dexdor??) in Clinical Practice.
    Stein D, Weatherall M, Garratt C, Aantaa R, Conti G, Lewis MA, Moore N, Gutthann S.
    Value Health. 2015